On Tuesday morning, Chimerix CEO Ken Moch was at the center of a media storm, maintaining that there was no way the biotech could responsibly provide its experimental antiviral to a dying child named Josh Hardy, a drug the boy's parents vowed was all that could save the child's life. By Tuesday night, though, Moch had found a way to give the treatment to the 7-year-old after all, as part of the clinical development program for the drug.
AngioDynamics said it won expanded FDA clearance for one of its key vascular access devices, a development that could help it boost the market reach for a product it bills as a healthcare cost-cutter.
Following a huge outcry from drugmakers, insurance companies, and patient advocates, the Obama administration said Monday it had abandoned proposed changes to the Medicare Part D drug benefit.
India's Ranbaxy Laboratories has issued another recall for its generic Lipitor, but a series of product recalls in recent weeks have come from plants around the world and companies as varied as Pfizer, Mylan and Gilead Sciences.
Mainstay Medical won approval from Ethics Committees in Australia to begin a clinical trial of its implantable neuromodulation device.
This week FDA officially introduced its push to open up its data to the public and particularly app developers. The unveiling went over the goals of openFDA, but also detailed some other areas in which the agency is investing. FDA is pushing hard into NGS and cloud-based genomics.
While most drugs from India are generics, sometimes Indian products are used by Big Pharma for their top brands, like AstraZeneca's Nexium.
Sleep drugs have been the root of plenty of safety worries over the years, especially when it comes to driving while under their influence. Now, just a week after the wrap of one of the highest-profile cases to revolve around Ambien generic zolpidem--Kerry Kennedy's--the European Medicines Agency's Pharmacovigilance Risk Assessment Committee is recommending updates to its product information to underscore the drug's associated risks.
AngioDynamics is gearing up for commercialization in the coming year for its latest chronic dialysis cathether, a product that will help protect and grow an already impressive U.S. market presence.
Reaping the benefits of deep-seated R&D reorganization, GlaxoSmithKline had the industry's best 6-year run of FDA nods for new drugs, according to EvaluatePharma, leading its competitors by a wide margin and leaving approval-starved outfits like Eli Lilly and Merck in the dust.